The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Apr 24, 2012

hi doc, how complera is more likely to select MDR HIV? if ever developed, what would be the next regimen to replace? is there any cheaper generic version of complera (like viraday for atripla)? regards.

Response from Dr. Young

Hi and thanks for posting.

It's not really clear what the basic mechanism that determines the genetic pattern of drug resistance is or why one drug regimen differs from another of the same classes. MDR HIV is selected after failure of many first-line regimens, but especially those that contain the popularly prescribed and recommended NRTI + NNRTI combo, such as Atripla or Complera. What has been observed in a large head-to-head study of these two single tablet regimens is that upon treatment failure, the Complera patients were more likely to harbor multidrug resistant virus.

Given the large number of current treatments, a second-line regimen after a Complera failure should be readily suppressed, but perhaps with a more complex drug regimen (but what wouldn't be more complex than 1 pill/day?)

Given that rilpivirine, the NNRTI in Complera was just FDA approved, there's no chance of a generic version of this (or Complera) anytime in the near future.

Hope that helps, BY

ginkgo and isentress and truvada

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint